Evidence map›Paper›PMID 30644008›Full record

ReviewJournal of neuro-oncology2019

5-ALA and FDA approval for glioma surgery.

Constantinos G Hadjipanayis, Walter Stummer

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of neuro-oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 191 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
191citing papers in PubMed, 6 pooled it
22.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

191 citing papers in PubMed, 6 syntheses or guidelines pooled it, 323 citations in OpenAlex.

  1. Pooled it
  2. 5-Aminolevulinic acid (5-ALA) in paediatric brain tumour surgery-a systematic review and exploration of fluorophore alternatives.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2025
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Trial
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review

131 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Constantinos G HadjipanayisIcahn School of Medicine at Mount Sinai, New York, NY, USA. constantinos.hadjipanayis@mountsinai.org.ORCID http://orcid.org/0000-0001-8615-6644
Walter StummerDepartment of Neurosurgery, Universitätsklinikum Münster, Münster, Germany.
Mount Sinai Beth Israel · USUniversity Hospital Münster · DE

Funding

Molecular Target Variation Across Environments and at Margins of GlioblastomaR01CA176659 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI BRAT, DANIEL J, HADJIPANAYIS, CONSTANTINOS GEORGE · 2013 to 2017
$2.3M
NCI NIH HHS R01 CA176659
6 · The paper itself

Abstract

The US Food and Drug Administration (FDA) approved 5-aminolevulinic acid (5-ALA; Gleolan

Indexed as

Aminolevulinic AcidFluorescent DyesOptical ImagingSurgery, Computer-AssistedBrain NeoplasmsDrug ApprovalGliomaHumansUnited StatesUnited States Food and Drug AdministrationAminolevulinic AcidFluorescent Dyes5-ALABrain tumorsFDAGlioblastomaGliomasHigh-grade gliomasIntraoperative imagingOptical imaging

Identifiers

PMID30644008
PMCPMC6445645
OpenAlexW2910072132

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.